SCHEMBL8515928

SCHEMBL8515928

Nc1cc(Cl)c(Oc2cccc(Cl)c2Cl)cc1N

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RHEB Q15382 1/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
NPSR1 Q6W5P4 2/20 0.46
TTR P02766 1/20 0.46
HSP90AA1 P07900 1/20 0.46
MAPT P10636 1/20 0.46
ALDH1A1 P00352 3/20 0.42
HTR1A P08908 1/20 0.39
SLC6A2 P23975 1/20 0.39
SLC6A4 P31645 1/20 0.39
SLC6A3 Q01959 1/20 0.39
GAA P10253 1/20 0.37
NPC1 O15118 1/20 0.37
TSHR P16473 1/20 0.35
PNMT P11086 1/20 0.35
KDM4E B2RXH2 1/20 0.35
HPGD P15428 1/20 0.35
ATM Q13315 1/20 0.35
NR4A2 P43354 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6325195 0.82 RHEB (0.60) RHEBMEN1KMT2ANPSR1TTR
SCHEMBL8515835 0.80 MEN1 (0.53) MEN1KMT2ANPSR1TTRHSP90AA1
SCHEMBL22069692 0.80 RHEB (0.45) RHEBMEN1KMT2ANPSR1TTR
SCHEMBL11053300 0.79 CYP3A4 (0.57) RHEBMEN1KMT2ANPSR1TTR
SCHEMBL28215828 0.79 NR4A1 (0.53) RHEBMEN1KMT2ANPSR1MAPT
SCHEMBL28141123 0.74 ALDH1A1 (0.40) RHEBMEN1KMT2ANPSR1TTR
SCHEMBL11453570 0.73 TTR (0.58) RHEBMEN1KMT2ATTRHSP90AA1
SCHEMBL11819263 0.73 CYP1A2 (0.59) MEN1KMT2ATTRMAPTALDH1A1
SCHEMBL22114111 0.73 MAPT (0.46) RHEBMEN1KMT2ANPSR1TTR
SCHEMBL22069620 0.73 SLC6A2 (0.45) RHEBMEN1KMT2ANPSR1TTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130303781-A1 PROCESS FOR PREPARATION OF TRICLABENDAZOLE SEQUENT SCIENTIFIC LIMITED (IN) 2013-11-14 US claimed
EP-2642995-A2 PROCESS FOR PREPARATION OF TRICLABENDAZOLE Sequent Scientific Ltd. (IN) 2013-10-02 EP claimed
WO-2012070068-A2 PROCESS FOR PREPARATION OF TRICLABENDAZOLE SEQUENT SCIENTIFIC LIMITED (IN) 2012-05-31 WO claimed
EP-3763706-A1 PARASITICIDAL COMPOSITIONS COMPRISING BENZIMIDAZOLE DERIVATIVES, METHODS AND USES THEREOF Boehringer Ingelheim Animal Health USA Inc. (US) 2021-01-13 EP disclosed
EP-3453702-A2 PARASITICIDAL COMPOSITIONS COMPRISING BENZIMIDAZOLE DERIVATIVES, METHODS AND USES THEREOF Merial, Inc. (US) 2019-03-13 EP disclosed
EP-2895465-B1 PARASITICIDAL COMPOSITIONS COMPRISING BENZIMIDAZOLE DERIVATIVES, METHODS AND USES THEREOF MERIAL INC (US) 2018-10-03 EP disclosed
US-9695129-B2 Parasiticidal compositions comprising benzimidazole derivatives, methods and uses thereof MERIAL INC. (US) 2017-07-04 US disclosed
US-9695129-B2 Parasiticidal compositions comprising benzimidazole derivatives, methods and uses thereof MERIAL INC. (US) 2017-07-04 US disclosed
US-9695129-B2 Parasiticidal compositions comprising benzimidazole derivatives, methods and uses thereof MERIAL INC. (US) 2017-07-04 US disclosed
CN-106632067-A Method for preparing triclabendazole serving as medicine for animal distomiasis 杭州洪桥生物技术有限公司 2017-05-10 CN disclosed
US-20160251317-A1 PARASITICIDAL COMPOSITIONS COMPRISING BENZIMIDAZOLE DERIVATIVES, METHODS AND USES THEREOF MERIAL INC (US) 2016-09-01 US disclosed
EP-2642995-A2 PROCESS FOR PREPARATION OF TRICLABENDAZOLE Sequent Scientific Ltd. (IN) 2013-10-02 EP disclosed
EP-2642995-A2 PROCESS FOR PREPARATION OF TRICLABENDAZOLE Sequent Scientific Ltd. (IN) 2013-10-02 EP disclosed
WO-2012070068-A3 PROCESS FOR PREPARATION OF TRICLABENDAZOLE SEQUENT SCIENTIFIC LIMITED (IN) 2012-07-19 WO disclosed
WO-2012070068-A2 PROCESS FOR PREPARATION OF TRICLABENDAZOLE SEQUENT SCIENTIFIC LIMITED (IN) 2012-05-31 WO disclosed
WO-2012070068-A2 PROCESS FOR PREPARATION OF TRICLABENDAZOLE SEQUENT SCIENTIFIC LIMITED (IN) 2012-05-31 WO disclosed
WO-2012070068-A2 PROCESS FOR PREPARATION OF TRICLABENDAZOLE SEQUENT SCIENTIFIC LIMITED (IN) 2012-05-31 WO disclosed
US-5322853-A For controlling or preventing an attack on plants by phytopathogenic microorganisms CIBA-GEIGY CORPORATION (US) 1994-06-21 US disclosed
EP-0462931-B1 Benzotriazole-1-sulfonyl derivatives with microbicidal properties CIBA GEIGY AG (CH) 1994-04-13 EP disclosed
EP-0462931-A1 Benzotriazole-1-sulfonyl derivatives with microbicidal properties CIBA-GEIGY AG (CH) 1991-12-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303781-A1 PROCESS FOR PREPARATION OF TRICLABENDAZOLE NIT2, CA3, TET3 RHEB 4307/4885MEN1 1675/4885KMT2A 455/4885
US-20160251317-A1 PARASITICIDAL COMPOSITIONS COMPRISING BENZIMIDAZOLE DERIVATIVES, METHODS AND USES THEREOF LIPC, CYP3A43, CYP51A1 RHEB 3425/4885MEN1 3898/4885KMT2A 3121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.